(.50 versus #50 ) was deemed. The anti-MET monoclonal antibody onartuzumab (MetMab) is presently
(.50 versus #50 ) was deemed. The anti-MET monoclonal antibody onartuzumab (MetMab) is presently getting investigated inside a randomized, double-blind, placebo-controlled, Phase II study in conjunction with bevacizumab plus mFOLFOX-6…